Cilento Richard C. Jr. 4

What Happened

• Richard C. Cilento Jr., a director of FibroBiologics, was granted 30,803 derivative securities on 2026-06-23. The report shows an acquisition price of $0.00 (award/derivative), meaning this was a compensation grant rather than a cash purchase.

Key Details

• Transaction date: 2026-06-23; reported same day (filing date 2026-06-23).
• Amount: 30,803 derivative shares/options; price shown: $0.00; total reported acquisition value: $0.
• Transaction code: A (award/grant); the filing classifies the instrument as a derivative.
• Shares owned after transaction: not provided in the Form 4 filing.
• Footnote: The options will vest in full upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting.

Context

• This was an equity award (derivative/option grant) as part of compensation for a director — common and not the same as an open-market purchase. The $0.00 acquisition reflects a grant rather than out-of-pocket purchase. Vesting is scheduled to occur within about a year (or earlier at the next annual meeting), which determines when Cilento can exercise or otherwise benefit from the award.